ES2156763A1 - Formulacion estables de solucion de apomorfina. - Google Patents

Formulacion estables de solucion de apomorfina.

Info

Publication number
ES2156763A1
ES2156763A1 ES009902380A ES9902380A ES2156763A1 ES 2156763 A1 ES2156763 A1 ES 2156763A1 ES 009902380 A ES009902380 A ES 009902380A ES 9902380 A ES9902380 A ES 9902380A ES 2156763 A1 ES2156763 A1 ES 2156763A1
Authority
ES
Spain
Prior art keywords
stable
solution formulations
solution
apomorphine solution
apomorphine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009902380A
Other languages
English (en)
Other versions
ES2156763B1 (es
Inventor
Eva Bernini
Gaetano Brambilla
Paolo Chiesi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of ES2156763A1 publication Critical patent/ES2156763A1/es
Application granted granted Critical
Publication of ES2156763B1 publication Critical patent/ES2156763B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulaciones estables de solución de apomorfina. Una formulación que contiene clorhidrato de apomorfina hemihidrato en solución acuosa en combinación con excipientes, siendo estable dicha solución durante al menos dos años a una temperatura de hasta 25°C y capaz de garantizar un bajo contenido microbiano después de la apertura y durante el uso.
ES009902380A 1998-10-30 1999-10-28 Formulaciones estables de solucion de apomorfina. Expired - Fee Related ES2156763B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998MI002331A IT1303684B1 (it) 1998-10-30 1998-10-30 Formulazioni di apomorfina in soluzione stabili nel tempo.

Publications (2)

Publication Number Publication Date
ES2156763A1 true ES2156763A1 (es) 2001-07-01
ES2156763B1 ES2156763B1 (es) 2002-03-01

Family

ID=11380970

Family Applications (1)

Application Number Title Priority Date Filing Date
ES009902380A Expired - Fee Related ES2156763B1 (es) 1998-10-30 1999-10-28 Formulaciones estables de solucion de apomorfina.

Country Status (6)

Country Link
BR (1) BR9905305A (es)
ES (1) ES2156763B1 (es)
FR (1) FR2785188B1 (es)
GB (1) GB2343376B (es)
GR (1) GR990100373A (es)
IT (1) IT1303684B1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02003312A (es) * 1999-09-29 2002-10-04 Procter & Gamble Composiciones que tienen estabilidad mejorada.
TW200526268A (en) * 2003-12-17 2005-08-16 Takeda Pharmaceutical Injectable composition
TW201035054A (en) * 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
DK2854764T3 (en) 2012-06-05 2019-04-08 Neuroderm Ltd COMPOSITIONS CONTAINING APOMORPHINE AND ORGANIC ACIDS, AND APPLICATIONS THEREOF
WO2015157212A1 (en) * 2014-04-10 2015-10-15 Us Worldmeds, Llc Stable apomorphine composition and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BROOKES, R.W. et al. An investigation of the stability of apomorphine injection upon sterilisation. The Pharmaceutical Journal, 1991, Vol. 247, paginas R11-R11A, ISSN 0031-6873. Todo el documento. *
ESSINK, A.W. and RUTTEN, W.J. Bereiding van apomorfine neusspray. Pharmacentisch Weekbland, 1991, Vol. 126, no 44, paginas 1113-1114, ISSN 0031-6911. Todo el documento. *
JAEGER. R.W. et DE CASTRO, F.J. Apomorphine: A Stable solution. Clinical Toxicology, 1976, Vol. 9, No 2, paginas 199-202. Todo el documento. *
LUNDGREN, P. et LANDERSJö, L. Stability and stabilization of apomorphine hydrochloride in aqueous solution. Acta Pharm. Suecica. 1970, Vol. 7, No 2, paginas 133-148, ISSN 0001-6675. Todo el documento. *
PANDOLFO, V. et al. Stabilita di formulazioni parenterali di apomorfine. Boll. Chim. Farm., 1984, Vol. 123, No 9, paginas 449-452, ISSN 0006-6648. Todo el documento. *
WILCOX, R.E. et al. Stability of apomorphine in solutions containing ascorbic acid and bisulfite and effects of antioxidants on apomorphine-induced cage climbing and hypothermia in mice. J. Pharm. Sci., 1980, Vol. 69, No 8, paginas 974-976, ISSN 0022-3549. Todo el documento. *

Also Published As

Publication number Publication date
FR2785188A1 (fr) 2000-05-05
IT1303684B1 (it) 2001-02-23
GR990100373A (el) 2000-06-30
GB2343376A (en) 2000-05-10
ES2156763B1 (es) 2002-03-01
FR2785188B1 (fr) 2004-10-29
BR9905305A (pt) 2001-03-20
GB9925602D0 (en) 1999-12-29
GB2343376B (en) 2003-12-31
ITMI982331A1 (it) 2000-04-30

Similar Documents

Publication Publication Date Title
MY129356A (en) Electrospun pharmaceutical compositions
CA2258841A1 (en) Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
EP0679390A3 (en) Sprayable topical pharmaceutical compositions
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
HK1024182A1 (en) Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations
SE9503143D0 (sv) New preparation
ZA200305412B (en) 4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical.
MY135988A (en) Additive for improving the water resistance of cosmetic or dermatological formulations
MY130477A (en) Pharmaceutical compositions for the treatmen of mucositis, stomatitis and behcet,s syndrome
IL208697A0 (en) Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
GEP20002332B (en) Cefalosporin Derivatives
AR012438A1 (es) Preparacion liquida antiacida libre de conservadores que es de ph estable, durante su vida de almacenamiento
BG103325A (en) Analgetic preparation for external application
MXPA03011480A (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral.
NZ511085A (en) Oral pharmaceutical compositions containing buprenorphin
MXPA03005221A (es) Composicion farmaceutica de dronedarona para administracion parenteral.
EP1980249A3 (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
DK0901790T3 (da) Anvendelse af moxonidin til behandling af neuropatisk smerte
ES2156763A1 (es) Formulacion estables de solucion de apomorfina.
HK1045458A1 (en) Ophthalmic histtamine compositions and uses thereof.
GB9905663D0 (en) Iodine preparation composition
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
DK0973505T3 (da) Vandigt farmaceutisk præparat, der omfatter en aktiv ingrediens, som er meget tungt opløselig i vand
BR9812385A (pt) Formulações parasiticidas
WO2001022917A8 (en) Effervescent compositions comprising nimesulide

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20010701

Kind code of ref document: A1

Effective date: 20010701

FD2A Announcement of lapse in spain

Effective date: 20180807